Navigation Links
ofatumumab in Medical News

Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma

Summary: Genmab has Initiated a Phase II Study of Ofatumumab in Relapsed Diffuse Large B-Cell Lymphoma COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that study centers have been initiated and are ready to enroll patients in...

Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program

Summary: Genmab and GSK Have Announced the Initiation of the Phase III Program With Ofatumumab to Treat Rheumatoid Arthritis. COPENHAGEN, Denmark, November 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the ...

GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer

...t (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal antibody a...se effects.(4) "The submission of the BLA for ofatumumab brings us closer to the possibility of providing a... in these patient groups treated with single-agent ofatumumab was 58 percent for the fludarabine alemtuzumab ref...

GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL

...ision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This ...

Genmab Announces 2008 First Half Year Results

...follows: We achieved a development milestone for ofatumumab (HuMax-CD20(R)) under the collaboration with Glaxo...evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA). We... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...onstrained environment limits off-label use. Market sales will also be driven by the introduction of four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for...

GlaxoSmithKline Presents Innovative Neuroscience Pipeline

...arketed therapies -- Phase II program for use of ofatumumab in multiple sclerosis announced, with trials i...r more effective and more convenient treatments. ofatumumab (HuMax-CD20), a promising monoclonal antibody, wil...ine Seretide TORCH Volibris (EU) ofatumumab (RA) (EU) Tykerb (US) Requip XL (PD) (U...
ofatumumab in Medical Technology

Recruitment Completed in Ofatumumab NHL Pivotal Study

Summary: Genmab has Completed Recruitment of Patients in the Phase III Study of Ofatumumab in Rituximab Refractory Follicular NHL COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has completed recruitment of patients in the pivotal Phase III st...

Genmab Announces Upcoming Ofatumumab Studies

Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies Planned COPENHAGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- Genmab has announced plans to begin four studies of ofatumumab in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

Summary: Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets Primary Endpoint COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today positive top-line results from an interim analysis of ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

COPENHAGEN, Denmark, July 9 /PRNewswire-FirstCall/ -- Summary: Genmab has completed recruitment of patients in the Phase II study of ofatumumab in combination with fludarabine and cyclophosphamide to treat front line CLL. Genmab A/S (OMX: GEN) announced today it has completed recruitment of ...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached a Milestone in its Ofatumumab Collaboration With GlaxoSmithKline COPENHAGEN, June 30 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached a development milestone for ofatumumab (HuMax-CD20(R)) under the terms of its...

Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study

COPENHAGEN, Denmark, June 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today a Phase I/II study to evaluate a subcutaneous route of administration of ofatumumab (HuMax-CD20(R)) in rheumatoid arthritis (RA) patients, stable on methotrexate will be initiated soon. The study, whic...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

...ease is refractory to fludarabine and alemtuzumab. ofatumumab is an investigational treatment. "The committee's positive vote in support of ofatumumab is a potential milestone for patients with CLL. Wh...ies. "The positive vote by ODAC confirms that ofatumumab may offer a new treatment option for patients who ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who h...ia (CLL). The results demonstrate the potential of ofatumumab for heavily pre-treated patients with CLL who do n...merican Society of Hematology, 6-9 December, 2008. ofatumumab is an investigational drug that has not been appro...

Genmab Announces Updates on Phase III Cancer Studies

...nterim analysis (N=132 patients) in the pivotal Phase III clinical trial of ofatumumab (HuMax-CD20(R)) in refractory chronic lymphocytic leukemia (CLL) has now re...cation in this indication is expected to be filed before the end of 2008. ofatumumab is an investigational drug being developed to treat CLL, follicular non-Hod...

GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)

...(abstract number: OPO232) from a Phase II study of ofatumumab (HuMax-CD20(R)) in patients with rheumatoid arthritis (RA). ofatumumab is being co-developed under a worldwide agreement ...f four treatment groups (300 mg, 700 mg or 1000 mg ofatumumab or placebo) and assessed based on their of Rheumat...
ofatumumab in Biological Technology

Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH

Responses Significantly Correlated to Overall Survival Summary: Three ofatumumab Abstracts Have Been Accepted for Presentation at the ASH Meeting December 6-9, 2008 COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that three of...

Genmab Reaches Milestone in Ofatumumab Collaboration

Summary: Genmab has Reached the Sixth Milestone in its Ofatumumab Collaboration With GSK. COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms ...

Genmab Reaches Fifth Milestone in Ofatumumab Collaboration

Summary: Genmab Will Receive a Milestone Payment of Approximately DKK 232.7 Million From GSK for Achievement of Positive Results in the Phase III CLL Study COPENHAGEN, August 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the fi...

Genmab Reaches Milestones in Ofatumumab Collaboration

Summary: Genmab has Achieved Two Development Milestones in its Ofatumumab Collaboration With GlaxoSmithKline. COPENHAGEN, January 21 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the second and third development milestones for ofatumumab (HuMax-...

Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis

Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis COPENHAGEN, Denmark, December 13 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20...

Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed i...

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study

Summary: Genmab has Amended the Design of the Ofatumumab Pivotal Study in Rituximab Refractory Follicular Non-Hodgkin's lymphoma and Reduced the Number of Patients to Approximately 81 COPENHAGEN, September 27 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it ...

Genmab Announces Encouraging Preclinical Data for ofatumumab

Summary: Genmab Announces ofatumumab Appeared More Effective Than rituximab in a Pre-Clinical Study COPENHAGEN, Denmark, September 7 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today that ofatumumab (HuMax-CD20(R)) appeared more effective at inducing compleme...

Genmab Announces Results for the First Nine Months of 2008

... results from a Phase III pivotal study evaluating ofatumumab (HuMax-CD20(R)) in two groups of patients with chr...nt. We completed recruitment in a second pivotal ofatumumab study in refractory non-Hodgkin's Lymphoma (NHL) p... We announced plans to begin four studies with ofatumumab this year: 1) Phase III CLL front line chlorambu...

Genmab Announces Year End 2007 Financial Results

...xpenses. Of the research and development costs, we expect to spend approximately DKK 500 million (approximately USD 98 million) on development for the ofatumumab program. Total projected revenues for 2008 are expected to be approximately DKK 1.0 billion (approximately USD 197 million), an increase of approxim...
Other Tags
(Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
(Date:10/22/2014)... 22, 2014 The Louis ... is dedicated to distribute health information technology innovation ... worldwide announced the development of six key guiding ... when receiving healthcare. These are an expansion of ... “providing care that is respectful of and responsive ...
(Date:10/22/2014)... Best Cheap Hosting USA is among ... site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) ... from around the world. , “iPower is one of ... is providing various kinds of useful products for new ... offering excellent customer service and a number of features ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
Other Contents